KOSPIBiotech & Pharma003220

Daewon Pharmaceutical

₩7,770▼ 0.89%2026-11-18 close
Market Cap
₩174.3B
Turnover
₩100M
Volume
20K
Shares out.
22.4M
PER
13.2×
PBR
0.7×
EPS
₩590
Dividend Yield
3.84%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩300 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrow, but sales have fallen for three straight quarters

Cumulative operating profit turned positive through 3Q 2026, but sales have declined for three straight quarters, so progress toward the 35% chronic-disease sales target by 2028 is the next checkpoint.

  1. 1

    Cumulative operating profit for the first nine months of 2026 was KRW 0.3 billion, turning from an operating loss of KRW 2.4 billion a year earlier (company announcement, November 13, 2026).

  2. 2

    Annual operating profit fell from KRW 43 billion in 2022 to KRW 3.48 billion in 2025, when the operating margin was 0.6%. Net income attributable to controlling shareholders swung to a net loss of KRW 1.38 billion.

  3. 3

    The company targets raising the share of chronic-disease products in sales from 21% in 2024 to 35% by 2028.

  4. 4

    The debt-to-equity ratio rose from 82.3% in 2022 to 123.5% in 2025, a trend of growing debt relative to equity.

  5. 5

    Respiratory and seasonal products and drug price cuts are the main drivers of sales swings, and 4Q 2026 is the winter respiratory season the company says it is preparing for.

02

Business structure

Daewon Pharmaceutical is a mid-sized pharmaceutical company founded in 1958 whose core business is manufacturing and selling medicines, organized into three segments: pharmaceuticals, health functional foods, and cosmetics.

According to the company's announcement on November 13, 2026, cumulative segment sales for the first nine months of 2026 were KRW 376.9 billion in pharmaceuticals (81.1% share), KRW 69.8 billion in health functional foods (15.0%), and KRW 17.6 billion in cosmetics (3.8%).

The segment amounts add up to more than consolidated sales of KRW 450.2 billion for the same period, so they appear to be stated before intersegment eliminations.

Within pharmaceuticals, cardiovascular and endocrine drugs were the largest group at KRW 92.7 billion, followed by respiratory drugs at KRW 79.4 billion, antipyretic, analgesic and anti-inflammatory drugs at KRW 68.6 billion, and gastrointestinal drugs at KRW 35.2 billion.

Reports cite a 16.1% prescription share in respiratory drugs in the first quarter of 2026, ranking the company first in Korea. Seasonal products such as Felubi (antipyretic, analgesic, anti-inflammatory) and Kodaewon (expectorant) have long driven sales.

The company aims to raise the share of chronic-disease products from 21% in 2024 to 35% by 2028, and the Idalbi family of hypertension treatments generated about KRW 3.5 billion in sales in the first quarter of 2026.

In health functional foods, the sleep supplement Kkuljamsot and the hair and skin product Moball Collagen 3X drove first-half 2026 sales of KRW 20.7 billion.

Exports are small, with domestic sales at 94.7% according to a 2025 report, and products are sold in about 30 countries including Southeast Asia, Latin America, the Middle East and Africa. R&D spending was reported at 8.68% of sales in 2024 and 9.24% (KRW 6.78 billion) in the first quarter of 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩143.9B-₩10.4B−7.2%
2025Q4₩159.8B₩5.9B3.7%
2026Q1₩158.1B₩4.4B2.8%
2026Q2₩152.8B-₩8,919,930−0.0%
2026Q3₩139.3B-₩4.1B−2.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩478.9B₩43B₩31.9B9.0%12.7%82.3%
2023₩527B₩32.2B₩23.9B6.1%9.0%92.2%
2024₩598.2B₩28.2B₩14.2B4.7%5.2%105.0%
2025₩605.4B₩3.5B-₩1.4B0.6%−0.5%123.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a reported basis, annual sales rose from KRW 478.9 billion in 2022 to KRW 527 billion in 2023 (up 10.0% year on year), KRW 598.2 billion in 2024 (up 13.5%), and KRW 605.4 billion in 2025 (up 1.2%). Sales have increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025.

Operating profit over the same period fell from KRW 43 billion in 2022 to KRW 32.2 billion in 2023 (down 25.1%), KRW 28.2 billion in 2024 (down 12.4%), and KRW 3.48 billion in 2025 (down 87.7%).

Operating profit has declined for three consecutive years from 2023 through 2025, and 2025 was the smallest year of the period. As a result, the operating margin fell from 9.0% in 2022 to 6.1%, 4.7% and 0.6% in 2025.

Sales grew while margins compressed, and the company attributed the first-half 2026 decline in operating profit to higher new-drug R&D and new-product marketing costs.

Net income attributable to controlling shareholders fell from KRW 31.9 billion in 2022 to KRW 23.9 billion in 2023 (down 25.1%) and KRW 14.2 billion in 2024 (down 40.6%), before swinging to a net loss of KRW 1.38 billion in 2025.

Total net income including non-controlling interests was a net loss of KRW 4.01 billion in 2025, a different figure from the controlling-shareholder measure.

Quarterly sales peaked at KRW 159.8 billion in 4Q 2025 and then fell to KRW 158.1 billion in 1Q 2026, KRW 152.8 billion in 2Q and KRW 139.3 billion in 3Q, three consecutive quarterly declines.

Operating profit moved from a KRW 10.4 billion loss in 3Q 2025 to KRW 5.85 billion profit in 4Q 2025, then KRW 4.38 billion in 1Q 2026 (down 25.2%), followed by an operating loss of KRW 8.92 million in 2Q and KRW 4.05 billion in 3Q, two straight loss-making quarters.

The 3Q 2026 loss was narrower than the KRW 10.4 billion loss a year earlier. Controlling-shareholder net income of KRW 13.6 billion in 4Q 2025 far exceeded that quarter's operating profit of KRW 5.85 billion, which suggests non-operating items may have had a large effect.

Controlling-shareholder net income for the last four quarters totaled KRW 13.2 billion. Operating cash flow was KRW 42.3 billion in 2025, well above the KRW 3.48 billion operating profit, so the gap between cash generation and earnings warrants attention.

Debt-to-equity was 123.5% at the end of 2025, with total liabilities of KRW 339.1 billion against total equity of KRW 274.6 billion, of which KRW 265.9 billion belongs to controlling shareholders.

05

Industry analysis

Respiratory drugs are highly seasonal, with the third quarter typically a slow period and the fourth quarter the peak. One analysis of standalone figures found that 4Q sales were the highest quarter in 2021 and 2023.

In 3Q 2026, the government's drug price cut policy, which affected the pharmaceutical industry broadly, and weaker demand for respiratory drugs were cited as reasons for lower sales.

Generic-heavy respiratory products are exposed to drug price re-evaluation risk, and the company is trying to reduce that dependence by developing higher-value improved new drugs and combination products.

A reported 16.1% prescription share in respiratory drugs in the first quarter of 2026, ranking first in Korea, can be read as a strength of its prescription base, though it has to be viewed alongside the seasonal product mix.

The chronic-disease market, covering hypertension, diabetes and dyslipidemia, is prescribed steadily throughout the year, and mid-sized Korean drugmakers compete there through improved new drugs and combination products.

Unlike listed peers such as Samsung Biologics or Alteogen, which rely on contract manufacturing or technology licensing, Daewon Pharmaceutical is built around prescription and consumer health products.

R&D spending runs at roughly 8% to 9% of sales, a high level, while operating profit recovery has been limited relative to sales. In the broader market, the GLP-1 class of obesity drugs is growing, and the company reported in 2025 that a patch-type obesity candidate succeeded in a Phase 1 trial.

06

Outlook

In its 3Q 2026 announcement, the company said it would respond actively to winter respiratory demand in 4Q and keep growing its chronic-disease and consumer healthcare businesses to lift sales and improve profitability together.

Because 4Q 2025 sales of KRW 159.8 billion were the seasonal peak, whether 4Q 2026 sales approach that level is the first checkpoint. The chronic-disease target is 35% of sales by 2028, and the company has said it plans to widen the product lineup with proprietary combination products.

Reports indicate that proprietary new products for diabetes, hypertension and dyslipidemia were launched in 2026. The Idalbi family generated about KRW 3.5 billion in sales in the first quarter of 2026, and its quarterly trend will show how fast the chronic-disease target is being reached.

In consumer healthcare, new product launches lifted health functional food sales to KRW 20.7 billion in the first half of 2026. The company has pointed to cost efficiency in the second half as a route to better profitability.

On R&D, the company said it has built a pipeline of 15 new and improved new drugs, and a patch-type obesity candidate was reported to have succeeded in a Phase 1 trial. Whether that candidate moves into the next clinical stage is a further checkpoint.

If drug price cuts continue, they could add pressure on respiratory product sales, so how much new product revenue offsets that pressure is the point to watch.

07

Valuation

PER
13.2×
PBR
0.7×
ROE
5.1%
EPS
₩590
BPS
₩11,644
Dividend per share
₩300

The price-to-book ratio is below 1x, meaning the market capitalization sits below the KRW 265.9 billion of equity attributable to controlling shareholders at the end of 2025. On an asset basis, the comparison shows only that the share price is trading under book net assets.

Operating margin was 0.6% in 2025, so the profit generated by those assets was limited, and the net-asset comparison should be read together with the pace of earnings recovery.

Earnings-based multiples are sensitive to quarterly swings, since controlling-shareholder net income for the last four quarters totaled KRW 13.2 billion. Because the company swung to a net loss attributable to controlling shareholders in 2025, annual earnings-based multiples can vary widely from year to year.

Dividend yield moves with the share price, so it is best read alongside the dividend decisions the company has disclosed.

Within the sector, the comparison must account for the company's mix of prescription respiratory drugs and health functional foods, and it is hard to compare directly with technology-licensing biotech companies.

Debt-to-equity rising from 82.3% in 2022 to 123.5% in 2025 shows a larger debt burden relative to equity, which together with the multiples indicates the scale of financial risk.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Smaller losses and a cumulative profit

The company said 3Q 2026 operating loss narrowed to KRW 4.05 billion from KRW 10.4 billion a year earlier, and the operating margin improved from -7.2% to -2.9%. Cumulative operating profit of KRW 0.3 billion for the first nine months reversed a KRW 2.4 billion operating loss a year earlier.

Controlling-shareholder net income swinging to KRW 13.6 billion in 4Q 2025 can also be read as a sign of recovering earnings capacity.

Progress in the chronic-disease shift

Cardiovascular and endocrine drugs reached KRW 92.7 billion in cumulative 2026 sales through 3Q, the largest pharmaceutical group and above the KRW 79.4 billion for respiratory drugs. The Idalbi family generated about KRW 3.5 billion in 1Q 2026 sales.

The company's argument is that a larger share of year-round chronic-disease prescriptions would reduce seasonal swings.

Growth outside respiratory products

According to the company, first-half 2026 health functional food sales were KRW 20.7 billion, led by the sleep product Kkuljamsot and the hair and skin product Moball Collagen 3X. Health functional foods were 15.0% of cumulative sales through 3Q 2026.

The core argument on the bullish side is that non-respiratory sales are filling the gap left by drug price cuts on respiratory products.

09

Bear factors

Sales down for three straight quarters

Sales fell to KRW 158.1 billion in 1Q 2026, KRW 152.8 billion in 2Q and KRW 139.3 billion in 3Q, three straight quarterly declines, and 3Q sales were down 3.2% year on year. The company attributed the drop to drug price cuts and weaker respiratory demand. If sales keep falling, holding a profit becomes harder for a business with substantial fixed costs.

Annual margin erosion and quarterly losses

Operating profit fell from KRW 43 billion in 2022 to KRW 3.48 billion in 2025, with a 0.6% operating margin. Net income attributable to controlling shareholders swung to a net loss of KRW 1.38 billion in 2025. Operating losses in 2Q and 3Q 2026 mean two straight loss-making quarters.

Seasonality dependence and financial burden

Respiratory products combined with antipyretic, analgesic and anti-inflammatory products accounted for 38% of sales in 2024, which has drawn criticism for making results highly seasonal. Total liabilities were KRW 339.1 billion at the end of 2025, and the debt-to-equity ratio of 123.5% was higher than 82.3% in 2022. Generic price re-evaluation risk is concentrated in respiratory products, adding to the burden.

10

Risk factors

Drug pricing and policy

Government drug price cuts and generic price re-evaluation can lower unit prices for respiratory products and weigh directly on sales. The company cited drug price cuts as a reason for the 3Q 2026 sales decline.

Whether the shift toward higher-value improved drugs and combination products offsets this pressure is the key question.

Balance sheet and cash flow

Debt-to-equity was 123.5% at the end of 2025, with total liabilities of KRW 339.1 billion against total equity of KRW 274.6 billion. Operating cash flow of KRW 42.3 billion in 2025 far exceeded operating profit of KRW 3.48 billion, so the reason for the gap between cash generation and earnings needs to be identified. Borrowing levels can be found in the notes to the annual business report.

R&D and pipeline

R&D spending reached KRW 6.78 billion in 1Q 2026, or 9.24% of sales. New pipeline assets such as the patch-type obesity candidate are reported at early clinical stages, so costs could rise before any results arrive. The company cited higher new-drug R&D spending as a reason for the first-half decline in operating profit.

11

What to watch next

  1. December 2026 to February 2027

    Winter respiratory demand and 4Q 2026 sales. Because 4Q 2025 sales of KRW 159.8 billion were the peak, whether sales approach that level and whether operating profit stays positive are the points to check.

  2. Late March 2027

    The 2026 annual business report is due, disclosing full-year 2026 sales and operating margin. Whether these move from the 0.6% operating margin and 123.5% debt-to-equity seen in 2025 is the next check on the regular filing.

  3. Mid-May 2027

    Expected timing of the 1Q 2027 results, based on the 1Q 2026 results released on May 15, 2026. The points to watch are whether sales break the three-quarter decline and whether operating profit stays positive.

  4. 2028

    The target year for raising chronic-disease products to 35% of sales. How far the share has risen from 21% in 2024 shows the pace of the portfolio shift, with the Idalbi family and in-house combination products central to it.

12

Overall view

Daewon Pharmaceutical swung to cumulative operating profit of KRW 0.3 billion through 3Q 2026, but annual operating profit fell from KRW 43 billion in 2022 to KRW 3.48 billion in 2025, with a 0.6% margin.

Sales rose for three consecutive years to KRW 605.4 billion in 2025, but have fallen for three straight quarters since 1Q 2026.

On the bullish side, the 3Q 2026 operating loss narrowed to KRW 4.05 billion, and non-respiratory sales from cardiovascular, endocrine and health functional food products are reducing seasonal dependence.

On the bearish side, drug price cuts and weaker respiratory demand are weighing on sales, and a debt-to-equity ratio of 123.5% could become a burden if earnings recovery is slow.

The net loss attributable to controlling shareholders of KRW 1.38 billion in 2025 and of KRW 6.81 billion in 3Q 2026 show how volatile quarterly results have been.

The next checkpoints are 4Q 2026 sales during the winter respiratory season from December 2026 to February 2027, the full-year operating margin in the annual business report due in late March 2027, and progress toward the 35% chronic-disease sales target for 2028. This report is an information-only document and does not contain an investment rating or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. daily.hankooki.com
  2. investing-for-everyone.com
  3. econovill.com
  4. m.etoday.co.kr
  5. supple.kr
  6. mt.co.kr
  7. pharm.edaily.co.kr
  8. m.etoday.co.kr
  9. thevaluenews.co.kr
  10. medicaltimes.com
  11. news.mtn.co.kr
  12. news.bizwatch.co.kr
  13. ttlnews.com
  14. medipana.com
  15. view.asiae.co.kr
  16. srtimes.kr
  17. specialtimes.co.kr
  18. dealsite.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis